Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter P

GENERIC NAME	TRADE NAME	CONDITION	STUDY CODE	STUDY NAME	ACCESS TO STUDY / PROTOCOL	ACCESS TO RESULTS
PAN PI3K INHIBITOR	Not marketed	Endometrial Neoplasms	ARD11436	NA	EudraCT: 2009-016707-30	Summary Results
PAN PI3K INHIBITOR	Not marketed	Breast Neoplasms	ARD11437	NA	NCT01082068	Summary
PAN PI3K INHIBITOR	Not marketed	Breast Neoplasms	ARD11439	NA	EudraCT: 2009-016862-10	Summary Results
PAN PI3K INHIBITOR	Not marketed	Solid Tumors	TCD11742	NA	NCT01357330	Summary
PAN PI3K INHIBITOR	Not marketed	Neoplasms	TED12863	NA	NCT01943838	Summary
PAN PI3K INHIBITOR	Not marketed	Solid Tumors	TED11883	NA	NCT01392924	Summary
PAN PI3K AND MTOR INHIBITOR	Not marketed	Lymphoma or Leukemia	ARD12130	NA	EudraCT: 2011-001616-57	Tabulated Results
PAN PI3K AND MTOR INHIBITOR	Not marketed	Indolent Lymphoma	TCD12012	NA	NCT01410513	Summary
PAN PI3K AND MTOR INHIBITOR	Not marketed	Glioblastoma	TED11605	NA	NCT01240460	Summary
PAN PI3K AND MTOR INHIBITOR	Not marketed	Neoplasms	TED12471	NA	NCT01596270	Summary
PAN PI3K AND MTOR INHIBITOR	Not marketed	Neoplasm Malignant	TED12414	NA	NCT01587040	Tabulated Results Posted
PARACETAMOL	Doliprane	Pain	PARAC_L_00859	NA	NCT00434681	Summary
PHOSPHATIDYL CHOLINE	Essentiale	Liver Disease	CHOLIL06301	EPLID	NCT02517385	Summary
PI3K-B INHIBITOR	Not marketed	Solid Tumors, Lymphoma	TCD12739	NA	NCT01673737	Summary
PLERIXAFOR	Mozobil	Non-Hodgkin's Lymphoma	ACT12781	NA	NCT02221492	Summary
PLERIXAFOR	Mozobil	Multiple Myeloma	ACT13710	NA	NCT02221479	Summary
PLERIXAFOR	Not marketed	Renal Impairment	AMD31001101	NA	NCT00445302	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma or Non-Hodgkin's Lyjmphoma	AMD3100-2104	NA	NCT00322387	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma or Non-Hodgkin's Lyjmphoma	AMD3100-2105	NA	NCT00322491	Tabulated Results
PLERIXAFOR	Not marketed	Hodgkin's Disease	AMD3100-2106	NA	NCT00396201	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma	AMD3100-2108	NA	NCT00396383	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma or Non-Hodgkin's Lyjmphoma	AMD3100-2109	NA	NCT00395967	Tabulated Results
PLERIXAFOR	Not marketed	Transplantation	AMD31002112	NA	NCT00396331	Tabulated Results
PLERIXAFOR	Mozobil	Non-Hodgkin's Lymphoma or Hodgkin's Disease	AMD31002113	NA	NCT00444912	Tabulated Results
PLERIXAFOR	Mozobil	Non-Hodgkin's Lymphoma	AMD31003101	NA	NCT00103610	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma	AMD31003102	NA	NCT00103662	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma or Non-Hodgkin's Lyjmphoma	AMD3100C201	NA	NCT00396266	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma or Non-Hodgkin's Lyjmphoma	AMD3100EU21	NA	NCT00322842	Tabulated Results
PLERIXAFOR	Mozobil	Multiple Myeloma	ARD12858-MOZ23510	NA	EudraCT: 2011-004783-30	Tabulated Results
PLERIXAFOR	Not marketed	Solid Tumors	MOZ15609-DFI12860	MOZAIC	EudraCT: 2010-019340-40	Tabulated Results
PLERIXAFOR	Mozobil	Non-Hodgkin's Lymphoma	EFC12482	NA	NCT01767714	Summary
PLERIXAFOR	Mozobil	Non-Hodgkin's Lymphoma	MOZ11809	NA	NCT01164475	Tabulated Results
PRISTINAMYCIN	Pyostacin	Infection	PRIST_L_01683	NA	NCT00393744	Summary
PROSTAGLANDINE E2 RECEPTOR ANGONIST	Not marketed	Open Angle Glaucoma or Ccular Hypertension	TDR13459	NA	NCT02531152	Summary
RIPK1 INHIBITOR	Not marketed	Amyotrophic Lateral Sclerosis	TDR16536	NA	NCT03757351	Summary

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted